Summary
This Form 8-K filing from Edwards Lifesciences Corporation (EW), dated July 23, 2007, announces the company's financial results for the second quarter of 2007. The filing primarily incorporates a press release detailing these results. While the full press release is attached as an exhibit, only specific portions are deemed "filed" under the Exchange Act, including the first two paragraphs and pages 6 through 10. Investors should refer to the press release for the detailed financial performance and operational highlights of the quarter. The key takeaway for investors is the disclosure of Q2 2007 financial performance. The report serves as a notification mechanism for these results, with the comprehensive details contained within the attached press release. Investors seeking to understand the company's recent financial health and operational trends should review the information provided in the press release Exhibit 99.1.
Key Highlights
- 1Edwards Lifesciences reported its second quarter 2007 financial results on July 23, 2007.
- 2The primary purpose of this 8-K filing is to announce and provide access to these Q2 2007 earnings.
- 3A press release detailing the financial results for the second quarter of 2007 is attached as Exhibit 99.1.
- 4Certain sections of the press release (first two paragraphs and pages 6-10) are considered "filed" under the Securities Exchange Act of 1934.
- 5The filing does not contain extensive new operational or financial data directly within the 8-K form itself, but rather directs investors to the accompanying press release.
- 6The Chief Financial Officer, Thomas M. Abate, signed the filing on behalf of the company.